GLPG1690 from Galapogas, receives orphan drug designation for idiopathic pulmonary fibrosis

Galapogas, a Belgium based drug developing company, has received orphan drug status for GLPG1690.

Release Date: 13-Oct-2016



Galapogas, a Belgium based drug developing company, has received orphan drug status for GLPG1690 to treat patients suffering from idiopathic pulmonary fibrosis, in Europe. GLPG1690 has unique approach to target a novel molecule, GPR84, a pro-inflammatory protein responsible for chronic low grade inflammatory diseases targets a novel molecule, GPR84, a pro-inflammatory protein responsible for chronic low grade inflammatory diseases.

 

 The drug yielded a positive result in efficacy, safety, and tolerability in phase 1 clinical investigation.

 

 Pulmonary fibrosis is a lung damaging disease including thick, stiff and scarred lungs. Affected lungs are not able to pump oxygen all over the body, as a result, the human brain does not receives the required oxygen.

 

For Orphan Drug Clinical Insight Reports Contact: neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.